Por: Forbes Tech November 15, 2022
Doctor viewing brain scans for possible disease or damage.getty In results posted today, Roche’s investigational Alzheimer’s Disease biologic, gantenerumab, to a statistically significant degree compared to placebo. The measured were remembering, solving problems, orientation, and personal care in patients suffering from early stages of Alzheimer's. Also, the level of removal of beta-amyloid plaque was lower than expected.... + full article
The Advocate USA Health November 07, 2022
Will the new experimental drug lecanemab for Alzheimer’s be available soon?In July, the U.S. Food and Drug Administration accepted an application for accelerated approval for lecanemab, and just recently, sponsors of the drug, Biogen and Eisai, announced positive results from... + más
Reimagining Alzheimer’s (Part 4): Cautious Optimism For A New Alzheimer’s Disease Treatment | Forbes
How To Spot The Early Signs Of Alzheimer's | Newsweek
Forbes USA Tech October 22, 2022
A person walks on a suspended rope bridge in the clouds. Extreme attraction.getty This article is the fourth installment in my series on Alzheimer’s disease. Read more about Alzheimer’s disease in , , and of the series. The pharmaceutical and biotech companies, Eisai and... + más
COVID-19 in seniors linked to increased Alzheimer’s risk, study finds | Portland Press Herald
Variety of factors play a role in the development of Alzheimer's | The Advocate
CNN USA Health October 04, 2022
CNN — The experimental Alzheimer’s drug lecanemab made big news last week when the companies testing it released trial results that showed the drug met its goals, making it one of the first dementia drugs to return positive results. In a randomized, placebo-controlled... + más
The Boston Globe USA Business September 29, 2022
Promising results from a trial of an experimental drug for Alzheimer’s made by Biogen and its Japanese partner Eisai are reviving hopes that an effective treatment for the devastating condition that’s long baffled the medical world may finally be at hand.In what some... + más
Biogen shares soar on Alzheimer's drug developments | Fox Business
Alzheimer's drug shows promise in early results of study | WPLG Local 10
Portland Press Herald USA Health September 28, 2022
An experimental Alzheimer’s drug slowed cognitive and functional decline by 27 percent in a closely watched clinical trial, the sponsors of the medication said Tuesday, increasing the therapy’s chance for approval as soon as early next year. Japanese drugmaker Eisai and its... + más
Alzheimer's drug slows progression of cognitive decline in clinical trial, drugmakers say | CNN
New test can detect plaques early in the disease: Alzheimer's Q&A | The Advocate
CNN USA Health September 28, 2022
CNN — A monoclonal antibody treatment for Alzheimer’s disease called lecanemab slows the progression of cognitive decline by 27% compared with a placebo, drugmakers Biogen and Eisai said Tuesday. The drug, tested in a Phase 3 global clinical trial, also met all secondary... + más
Experimental Alzheimer’s drug slows cognitive decline in trial, firms say | Portland Press Herald
The Advocate USA Health September 17, 2022
What is the Lumipulse test for Alzheimer’s disease?In May, the U.S. Food and Drug Administration permitted marketing of the Lumipulse (G B-Amyloid Ratio [1-42/1-40]) test to Fujirebio Diagnostics, Inc. of Malvern, Pennsylvania. The test, which was granted Breakthrough Device... + más
Alzheimer's Q&A: Sildenafil has potential as Alzheimer's drug | The Advocate
About iurex | Privacy Policy | Disclaimer |